|
|
|
|
|
|
|
|
|
04.03.26 - 22:03
|
AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND (PR Newswire)
|
|
|
THOUSAND OAKS, Calif., March 4, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.52 per share dividend for the second quarter of 2026. The dividend will be paid on June 5, 2026, to all stockholders of record as of the close of business on......
|
|
|
04.03.26 - 15:06
|
ImmunoScape Announces Memorandum of Understanding for Clinical Trial with Premier U.S. Cancer Center (Business Wire)
|
|
|
The company also announced a strategic investment from Leonardo DiCaprioSINGAPORE & SAN DIEGO--(BUSINESS WIRE)--ImmunoScape Pte. Ltd., an A*STAR spin-out backed by Amgen Ventures and EDBI that is developing next-generation TCR-based cancer immunotherapies, today announced the execution of a Memorandum of Understanding (MOU) with a premier NCI-designated Comprehensive Cancer Center in the United States, renowned globally for its pioneering history in cellular immunotherapy. This partnership will fast-track ImmunoScape's “Seed and Boost” platform into the clinic. Concurrently, the company announced a strategic investment from Leonardo DiCaprio.
Accelerating the “Seed and Boost” Clinical Program
Under the terms of the MOU, ImmunoScape will partner with the cancer center to launch an investigator-initiated clinical trial targeting Wilms Tumor 1 (WT1) positive solid tumors. The trial will focus on four difficult-to-treat indications: ovarian, mesothelioma, and other high-unmet need solid tumors such a...
|
|
|
|
|
|
|
|
|
|
|
|
|
21.02.26 - 00:12
|
The Analyst Verdict: Amgen In The Eyes Of 18 Experts (Benzinga)
|
|
|
Latest Ratings for AMGN
DateFirmActionFromTo Feb 2022Morgan StanleyMaintainsEqual-Weight Feb 2022Wells FargoMaintainsEqual-Weight Feb 2022BarclaysMaintainsEqual-Weight
View More Analyst Ratings for AMGN
View the Latest Analyst Ratings
Importance Rank:
1
read more...
|
|
|
20.02.26 - 18:39
|
Amgen Aktie: Die große Phase-3-Frage bleibt lange offen (Aktiencheck)
|
|
|
London (www.aktiencheck.de) - Amgen-Aktienanalyse von Barclays:
Barclays habe die Coverage der Aktie von Amgen Inc. (ISIN: US0311621009, WKN: 867900, Ticker-Symbol: AMG, NASDAQ-Symbol: AMGN) mit einem "equal weight"-Rating und einem Kursziel von 185 USD aufgenommen. Da bis zur Phase-3-Auswertung der MARITIME-Studie noch genügend Zeit sei, werde es beim größten Streitpunkt rund um Amgen noch eine Weile dauern, bis es konkrete Antworten gebe. [mehr]...
|
|
|
20.02.26 - 14:00
|
Here Are Friday′s Top Wall Street Analyst Research Calls: Amgen, ETSY, Eldorado Gold, GE Aerospace, Merck, Southern Company, Walmart, Yeti, and More (24/7 Wall St.)
|
|
|
Pre-Market Stock Futures: Futures are trading flat as we wrap up the holiday-shortened week that gave us a little taste of just about everything. While Walmart posted results that beat expectations, its forward guidance and outlook fell short of Wall Street's expectations, and the stock was down from the opening bell to the close. All ... Here Are Friday's Top Wall Street Analyst Research Calls: Amgen, ETSY, Eldorado Gold, GE Aerospace, Merck, Southern Company, Walmart, Yeti, and More
The post Here Are Friday's Top Wall Street Analyst Research Calls: Amgen, ETSY, Eldorado Gold, GE Aerospace, Merck, Southern Company, Walmart, Yeti, and More appeared first on 24/7 Wall St.....
|
|
|
|
|
18.02.26 - 22:48
|
Amgen Aktie: Diese Pipeline-Themen könnten der nächste Kurstreiber sein (Aktiencheck)
|
|
|
Minneapolis (www.aktiencheck.de) - Amgen-Aktienanalyse von Piper Sandler:
Piper Sandler habe nach einem Treffen mit dem Management das Kursziel das Kursziel für die Aktie von Amgen Inc. (ISIN: US0311621009, WKN: 867900, Ticker-Symbol: AMG, NASDAQ-Symbol: AMGN) von 381 auf 432 USD angehoben und das "overweight"-Rating bestätigt. [mehr]...
|
|
|
13.02.26 - 22:57
|
Corporate News: Amgen (EQS)
|
|
|
EUROPÄISCHE KOMMISSION GENEHMIGT UPLIZNA® VON AMGEN FÜR GENERALISIERTE MYASTHENIA GRAVIS...
|
|
|
|
|
13.02.26 - 11:36
|
Amgen receives EC approval for Uplizna in generalised myasthenia gravis (PBR)
|
|
|
This approval provides a new option for long-term disease control in patients, with twice-yearly maintenance dosing after two initial loading doses. gMG is a rare, chronic, B-cell-mediated autoimmune
The post Amgen receives EC approval for Uplizna in generalised myasthenia gravis appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
